Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT
Main Article Content
Keywords
bimekizumab, efficacy, long-term, psoriasis, plaque psoriasis, PASI, skin clearance, quality of life, 3 year
Abstract
Introduction: A key factor of biologic discontinuation in plaque psoriasis patients is loss of response over time; long-term treatment efficacy is therefore important.1 Here, 3-year efficacy of bimekizumab (BKZ) from a pooled analysis of patients with moderate to severe plaque psoriasis across 3 phase 3 clinical trials and their open-label extension (OLE) is reported.
Procedure/study: Data were pooled from the 52-week BE VIVID and 56-week BE SURE and BE READY phase 3 trials, and their common OLE BE BRIGHT.2–5 Included patients received BKZ 320 mg every 4 weeks (Q4W) then switched to Q4W or Q8W maintenance dosing from Week 16 onwards, and entered the OLE; from OLE Week 48 or the next scheduled visit, all patients received BKZ 320 mg Q8W. Proportions of patients achieving ≥90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90), PASI 100, and Dermatology Life Quality Index (DLQI) 0/1 are reported through Year 3 using modified non-responder imputation: patients who discontinued treatment due to lack of efficacy or treatment-related adverse events were considered non-responders at subsequent timepoints; multiple imputation was used for all other missing data.
Results: 771 patients received BKZ continuously in the feeder studies and entered the OLE. Among these, at Week 16, 90.9%, 65.8%, and 71.5% achieved PASI 90, PASI 100, and DLQI 0/1, respectively. At Year 1, 93.7%, 76.6%, and 83.1% of all BKZ-treated patients achieved PASI 90 (Week 52), PASI 100 (Week 52), and DLQI 0/1 (Week 48/52), respectively. Responses were durable to Year 3 (OLE Week 96): 91.0%, 70.3%, and 82.8% of all BKZ-treated patients achieved PASI 90, PASI 100, and DLQI 0/1, respectively. Similar trends were observed in the subset of patients that received BKZ Q4W/Q8W/Q8W (initial/maintenance/OLE).
Conclusion: High and durable clinical and health-related quality of life responses were observed over 3 years of BKZ treatment across 3 phase 3 trials and their OLE.
Funding: UCB Pharma.
References
2. Reich K et al. Lancet 2021;397:487–98, NCT03370133;
3. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747;
4. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992;
5. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.